Since the 1990s, multiple PIs have been approved, with several boosted PI regimens recognized as first-line regimens in antiretroviral therapy (ART -naive pART -naive
The reasons for nonadherence with a regimen, especially a medication regimen, is recognized as complex [38-41] [38-41]ludes, andng many others, lincludesor amongness barriers [42-47] and manycatiothersess barriers stemming from costs [48-51].
While access and adherence to the prescribed drug regimen is recognized as the most important determinant of treatment success [ 4], other factors, including clinical status at treatment initiation, specific illicit drug use patterns [ 5] and homelessness [ 6], may also play a role.
They also suggest that Kaplan Meier estimates may be preferred and that interpretation should consider how the predicted outcome varies by regimen and recognize that precision may be low.
To our knowledge, this is the first of its kind long-term clinical study comparing a cosmetic anti-ageing regimen against a recognized prescription topical treatment for improving the appearance of facial wrinkling.
To date, none of combination regimens has been recognized as a standard or superior to doxorubicin alone.
1– 8 However, new adverse events associated with various antiretroviral regimens were soon recognized, and were collectively referred to as the lipodystrophy syndrome.
However, due to lack of systematic investigation and poor understanding of TCM regimens, TCM is less recognized in the Western society.
The increased risk of hypoglycemia that comes with attempts to reduce A1C to target levels using intensive insulin regimens has long been recognized (9).
However, few reports have not observed increased weight gain during chemotherapy [ 5, 8, 9], in particular with anthracycline-containing regimens [ 10, 11] widely recognized as the gold standard treatment of women with breast cancer.
